PT-141

A melanocortin-receptor peptide approved in the US for low sexual desire in premenopausal women; phase 3 gains were small and nausea affected 40%.

Also known as: Bremelanotide, Vyleesi
Area: Hormones
Status: FDA-approved (Vyleesi, 2019) for HSDD in premenopausal women; not licensed in the UK

Articles on PT-141

SkinHuman RCT

Melanotan I and II: one became a licensed drug, the other a mole-changing tanning jab

Melanotan I, as afamelanotide, is approved for a rare light-sensitivity disease. Melanotan II was never approved, and case reports link it to changing moles and melanoma.

HPR Editorial · 18 Sept 2026 · 7 min read

HormonesHuman RCT

PT-141 (bremelanotide): what the RECONNECT trials found, and what they didn’t

Bremelanotide is FDA-approved for low sexual desire in premenopausal women. In phase 3 it raised desire scores modestly, didn’t increase satisfying sexual events, and caused nausea in 40%.

HPR Editorial · 10 Sept 2026 · 7 min read